Urendia 10 mg (Tablet)

Unit Price: ৳ 80.00 (1 x 10: ৳ 800.00)
Strip Price: ৳ 800.00

Medicine Details

Category Details
Generic Finerenone
Company Unimed unihealth pharmaceuticals ltd
Also available as
Urendia 20 mg tablet

Indications

  • Reduces risk of sustained eGFR decline
  • Reduces risk of end-stage kidney disease
  • Reduces risk of cardiovascular death
  • Reduces risk of nonfatal myocardial infarction
  • Reduces risk of hospitalization for heart failure

Pharmacology

  • Selective antagonist of the mineralocorticoid receptor (MR)
  • Blocks MR mediated sodium reabsorption in tissues
  • High potency and selectivity for the MR
  • Completely absorbed after oral administration
  • Metabolized by CYP3A4 and CYP2C8
  • Excreted in urine

Dosage & Administration

  • Recommended starting dosage of 10 mg or 20 mg orally once daily
  • Tablets may be taken with or without food
  • Target dose of 20 mg once daily
  • Dosage adjustment based on eGFR and serum potassium thresholds
  • Patients who are unable to swallow whole tablets can crush and mix with water or soft foods
  • Monitoring and dose adjustment of serum potassium
  • Instructions for missed doses

Interaction

  • Contraindicated with strong CYP3A4 inhibitors
  • Monitoring serum potassium with moderate and weak CYP3A4 inhibitors
  • Avoid concomitant use with strong or moderate CYP3A4 inducers

Contraindications

  • Contraindicated in concomitant use with strong CYP3A4 inhibitors
  • Contraindicated in patients with adrenal insufficiency

Side Effects

  • Adverse reactions include hyperkalemia, hypotension, and hyponatremia

Pregnancy & Lactation

  • No available data on use in pregnancy
  • Animal studies show developmental toxicity
  • No data on presence in human milk
  • Risk of exposure to breastfed infants
  • Avoid breastfeeding during treatment and for 1 day after treatment

Precautions & Warnings

  • Risk of hyperkalemia increases with decreasing kidney function
  • Measure serum potassium and eGFR before initiation of treatment
  • More frequent monitoring for patients at risk for hyperkalemia
  • Do not initiate if serum potassium is > 5.0 mEq/L

Use in Special Populations

  • Safety and efficacy not established in patients below 18 years of age
  • No overall differences in safety or efficacy observed in geriatric patients
  • Avoid use in patients with severe hepatic impairment
  • Consider additional serum potassium monitoring in patients with moderate hepatic impairment

Overdose Effects

  • Immediately interrupt treatment in the event of suspected overdose
  • Manifestation of overdose is hyperkalemia
  • Standard treatment for hyperkalemia should be initiated
  • Unlikely to be efficiently removed by hemodialysis

Therapeutic Class

  • Mineralocorticoid Receptor Antagonists

Storage Conditions

  • Store below 30°C
  • Keep away from light and moisture
  • Keep out of the reach of children

Related Brands